Aspire Biopharma Holdings, Inc. (ASBP) Stock

Aspire Biopharma Holdings, Inc. (ASBP) is a Healthcare stock trading at $7.99 (as of 2026-08-21), with a market capitalization of $11.21M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Aspire Biopharma Holdings, Inc. develops and markets sublingual delivery formulations in the United States, including Instaprin, a sublingual aspirin product, and other sublingually administered products it is developing such as sleep-aid, vitamins, testosterone, and semaglutide formulations. The company serves patients and customers seeking sublingual pharmaceutical options.

Understand Aspire Biopharma Holdings, Inc.: how it makes money

Aspire Biopharma develops and markets sublingual delivery products in the United States, including Instaprin (a soluble, pH neutral, fast acting aspirin) and a pipeline of other sublingual formulations, and it generates income from selling its marketed products and advancing those formulations toward commercialization.

The profit model depends on converting its sublingual delivery technology into commercially sold, marketed products, starting with Instaprin, while additional sublingual formulations are still in development.

Business quality (Weak): Based on the provided information, there is no clean reportable segment breakdown and no operational KPI labels available, so the operating drivers cannot be directly quantified from this dataset.

Valuation: At 0× earnings, ASBP trades 100% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

  • Differentiated product positioning: Instaprin is described as a soluble, pH neutral, fast acting sublingual aspirin product aimed at cardiology emergencies and pain management.
  • Breadth of sublingual pipeline: The company is also developing sublingual formulations including melatonin, vitamins D, E, and K, testosterone, semaglutide, and anti-nausea products.

Bear case

  • Early-stage execution risk: The company is described as early-stage, and many offerings are characterized as being developed, which can limit near-term commercial results.
  • Loss-making profitability in the latest quarter: For the quarter ended 2026-03-31, the provided data shows 0.0B revenue and a deeply negative operating margin of -5806.0%.
Valuation — source: SEC EDGAR (first-party)
Price$7.99
Market Cap$11.21M
Price / Book0.95
Price / Sales92.04
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$6202.00
Net Margin-394725.1%
Revenue Growth (YoY)-98.9%
Financial Health — source: SEC EDGAR
Altman Z-Score-80.36 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderAntara Capital LP ($26.76M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOKraig T. Higginson
Employees2
CountryUS
IPO Date2025-02-20

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • BioVie Inc. (BIVI)
  • Phio Pharmaceuticals Corp. (PHIO)
  • Moleculin Biotech, Inc. (MBRX)
  • Kiora Pharmaceuticals, Inc. (KPRX)
  • Bullfrog AI Holdings, Inc. Common Stock (BFRG)
  • Theriva Biologics, Inc. (TOVX)
  • MetaVia Inc. (MTVA)
  • Imunon, Inc. (IMNN)
ASBP earnings history · ASBP institutional & insider holders · ASBP KPIs & operating metrics · ASBP financials · ASBP investor presentations & press releases · ASBP SEC filings · ASBP peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.